AndrewMartinBellingerMDPhD

Preventive Cardiology

Chief Scientific Officer, Verve Therapeutics; Co-founder, Lyndra Therapeutics Co-founder, Corner Therapeutics Cardiovascular Medicine, Brigham and Women's Hospital

Join to view full profile

Dr. Bellinger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bellinger's full profile

Already have an account?

Office
75 Francis St
Division of Cardiology
Boston, MA 02115
Phone+1 857-307-4000

Education & Training

Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2011 - 2015
University of California (San Francisco)Residency, Internal Medicine, 2009 - 2011
Columbia University Vagelos College of Physicians and SurgeonsClass of 2009

Certifications & Licensure

MA State Medical License 2011 - 2026

Publications & Presentations

PubMed

54 citations
Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targetingin Nonhuman Primate and Mouse Models.
Richard G Lee, Anne Marie Mazzola, Maurine C Braun, Colin Platt, Scott B Vafai
Circulation. 2023-01-17
141 citations
Oral, ultra–long-lasting drug delivery: Application toward malaria elimination goals
Andrew Bellinger, Mousa Jafari, Tyler Grant, Shiyi Zhang, Hannah C Slater
Science Translational Medicine. 2016-11-16
22 citations
Changing the pill: developments toward the promise of an ultra-long-acting gastroretentive dosage form.
Altreuter David, Ameya R. Kirtane, Tyler Grant, Cecilia Kruger, Giovanni Traverso
Expert Opinion on Drug Delivery. 2018-11-13

Press Mentions

A Single Infusion of a Gene-Editing Medicine May Control Inherited High LDL CholesterolNovember 12th, 2023
Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-Type and LDLR-Deficient Non-Human PrimatesMarch 3rd, 2023
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial ResultsNovember 7th, 2022
Join now to see all

Professional Memberships

American College of Cardiology - ACC
Member